Early Investigation of Glucose Monitoring After Gestational Diabetes Pilot

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-50
SponsorOhio State University

About this trial

One third of women with gestational diabetes (GDM), diabetes diagnosed during pregnancy, have abnormal glucose levels within 3 years after pregnancy, but follow up is low. Continuous glucose monitors (CGM), a small sensor inserted under the skin, may be able to screen women with GDM for diabetes risk. The investigators will ask postpartum women to use CGM at 6-8 weeks postpartum and answer surveys about quality of life after wearing the CGM. The investigators will collect data on blood glucose trends for future studies if participants find CGM use acceptable. The investigators hope to learn if CGM could improve postpartum follow up experiences for people with recent GDM.

Eligibility criteria

Qualifiers

Women with a viable singleton intrauterine pregnancy

Able to understand the study, and having understood, provide written informed consent in English

Recent pregnancy affected by gestational diabetes

Disqualifiers

Pregestational Diabetes (Type I or Type II)

Continued use of diabetes medications (including metformin and insulin) immediately after delivery

Preterm delivery (< 37 weeks gestation)

Twin or higher order gestation

Trial design

Treatments tested in this trial

  • Continuous glucose monitor
  • Oral Glucose Tolerance Test
  • Hemoglobin A1c

Treatment groups

20 Participants
are divided into 1 treatment group

Locations

1
Ohio State University Medical Center43210, ColumbusOhio, United States

Sponsors and collaborators

Ohio State University

Lead sponsor

DexCom, Inc.

Collaborator